Medicofarma Biotech (WAR:MDB) Total Assets: zł13.84 Mil (As of Mar. 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
28 GF Score
Price zł0.44
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Total Assets?

Medicofarma Biotech WAR:MDB +1.84% 28 Total Assets is zł13.84 Mil as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 28/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Medicofarma Biotech's Total Assets for the quarter that ended in Mar. 2026 was zł13.84 Mil.

During the past 12 months, Medicofarma Biotech's average Total Assets Growth Rate was -4.80% per year. During the past 3 years, the average Total Assets Growth Rate was -3.60% per year. During the past 5 years, the average Total Assets Growth Rate was 66.20% per year. During the past 10 years, the average Total Assets Growth Rate was 43.00% per year.

During the past 13 years, Medicofarma Biotech's highest 3-Year average Total Assets Growth Rate was 242.70%. The lowest was -35.60%. And the median was -0.85%.

Total Assets is connected with ROA %. Medicofarma Biotech's annualized ROA % for the quarter that ended in Mar. 2026 was -16.38%. Total Assets is also linked to Revenue through Asset Turnover. Medicofarma Biotech's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Medicofarma Biotech  (WAR:MDB) Total Assets Explanation

Total Assets is connected with ROA %.

Medicofarma Biotech's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-2.296/( (14.203+13.835)/ 2 )
=-2.296/14.019
=-16.38 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Medicofarma Biotech's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.036/( (14.203+13.835)/ 2 )
=0.036/14.019
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Medicofarma Biotech Total Assets Related Terms

Medicofarma Biotech Total Assets Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech Total Assets Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.77 16.37 14.97 14.71 14.20

Medicofarma Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.53 14.09 13.75 14.20 13.84
WAR:MDB
28GF Score
Medicofarma Biotech SA WAR:MDB
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Medicofarma Biotech's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=5.683+8.519
=14.20

Medicofarma Biotech's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=5.109+8.726
=13.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of zł13.84 Mil mean?
Medicofarma Biotech (WAR:MDB) has a Total Assets of zł13.84 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Medicofarma Biotech and its competitors.
Is Medicofarma Biotech's Total Assets too high?
Medicofarma Biotech's current Total Assets is zł13.84 Mil. Overall, Medicofarma Biotech has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Total Assets compare to ZTS and UTHR?
Medicofarma Biotech's Total Assets of zł13.84 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Medicofarma Biotech and its competitors. Medicofarma Biotech's current Total Assets is zł13.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.44 — trading 784% above its estimated fair value. The current Total Assets is zł13.84 Mil. Medicofarma Biotech's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Total Assets is zł13.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.44 is trading 784% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Total Assets: zł13.84 Mil
  • GF Value™: zł0.05 vs. price of zł0.44 (784% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
28GF Score

Get the complete analysis for WAR:MDB

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.44
Price
zł0.05
GF Value